<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558710</url>
  </required_header>
  <id_info>
    <org_study_id>VibRate Study</org_study_id>
    <nct_id>NCT04558710</nct_id>
  </id_info>
  <brief_title>The Effect of Frequent Continuous Glucose Monitoring Use on Glucose Variability in Preschoolers With Type 1 Diabetes</brief_title>
  <official_title>The Effect of Frequent Continuous Glucose Monitoring Use on Glucose Variability in Preschoolers With Type 1 Diabetes - The VibRate Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ljubljana, Faculty of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Society for Pediatric and Adolescent Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinderkrankenhaus auf der Bult, Hannover, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Pediatrcs, Endocrinology and Diabetes Medical University of Silesia in Katowice, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pediatric Diabetes and Metabolic Disorders Unit, Regional Center for Pediatric Diabetes, University City Hospital of Verona, Verona, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University School of Medicine, Department of Pediatrics, New Haven, Connecticut, United States</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pediatric Endocrinology Unit, Paediatrics Department, Maternal and Paediatrics Centre, São João University and Hospital Centre, Porto, Porto, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Pediatrics, Section on Diabetes and Metabolism, V. Buzzi Children's Hospital, University of Milan, Milan, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pediatric Endocrinology Unit. Hospital Pediátrico. Centro Hospitalar e Universitário de Coimbra. Coimbra. Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diaboss, Amsterdam, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical School, University of Valparaiso, San Felipe, Chile.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Pediatric Endocrinology and Diabetes, Koç University Hospital, İstanbul, Turkey.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Pediatrics, Sapienza University of Rome, Rome, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Pediatrics, San Raffaele Scientific Institute , Milan, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ljubljana, Faculty of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether continuous glucose monitoring will improve&#xD;
      glucose variability as measured by the coefficient of variation of glucose levels in very&#xD;
      young children with T1D. The study adopts an open-label, multi-centre, multinational,&#xD;
      prospective registry-based population cohort design contrasting CGM use to SMBG alone in&#xD;
      young children with type 1 diabetes over 12 months.&#xD;
&#xD;
      The primary endpoint is the difference between treatment modalities (CGM vs SMBG alone) in&#xD;
      glycaemic variability, measured as the coefficient of variation of glucose levels, during the&#xD;
      12 months observational period. Other Key edpoints include time in range 70-180 mg/dl, time&#xD;
      below range 70 mg/dl and time above range 180 mg/dl.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Coefficient of variation</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in Range</measure>
    <time_frame>1 year</time_frame>
    <description>Time in Range 70 - 180 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Above Range</measure>
    <time_frame>1 year</time_frame>
    <description>Time in Range above 180 mg/dl</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">339</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Continuous Glucose Monitoring</condition>
  <condition>Children</condition>
  <condition>Glucose Variability</condition>
  <arm_group>
    <arm_group_label>CGM</arm_group_label>
    <description>CGM users</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMBG</arm_group_label>
    <description>Non-CGM users</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pre-school children below age of 7 years with type 1 diabetes (for at least 6 months) and&#xD;
        treated with insulin pump fo at least 3 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key inclusion criteria:&#xD;
&#xD;
          1. Age below 7 years of age (at inclusion)&#xD;
&#xD;
          2. Type 1 diabetes for at least 6 months&#xD;
&#xD;
          3. Insulin pump user for at least 3 months&#xD;
&#xD;
          4. Treated with rapid or ultra-rapid acting insulin analogue&#xD;
&#xD;
        Key exclusion criteria:&#xD;
&#xD;
          1. Physical or psychological disease likely to interfere with normal conduct of the study&#xD;
&#xD;
          2. Untreated coeliac disease or thyroid disease&#xD;
&#xD;
          3. Current treatment with drugs known to interfere with glucose metabolism&#xD;
&#xD;
          4. Subject/carer's severe visual impairment&#xD;
&#xD;
          5. Subject/carer's severe hearing impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Faculty - University of Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

